WEIGHT loss intervention improved breast cancer quality of life and symptoms in BWEL results presented at ASCO 2026.
Weight Loss Intervention and Breast Cancer Quality of Life
A lifestyle-based weight loss intervention improved multiple patient-reported quality of life and symptom outcomes among women with stage II–III breast cancer and elevated body mass index, according to prespecified secondary results from the BWEL trial presented at ASCO 2026.
BWEL, also known as Alliance A011401, is a Phase III trial evaluating a 24-month lifestyle-based weight loss intervention plus health education compared with health education alone. The trial enrolled patients with stage II–III breast cancer and a BMI of at least 27 kg/m². This analysis focused on the first 540 randomized patients, who entered the trial between September 2016 and July 2017 and completed patient reported outcome measures at enrollment, 6 months, and 24 months.
Patient Reported Outcomes Improved At 6 Months
At baseline, the median BMI was 32.9 kg/m², with a range of 26.5–69.1 kg/m², and the median age was 53 years. Most patients were non-Hispanic White, while 10.7% were Black and 5.9% were Hispanic.
At 6 months, the weight loss intervention arm showed significantly better physical function than health education alone, with an adjusted mean between arm difference of 1.9 points. Global physical health also improved, with a 2.0-point difference favoring the intervention, while global mental health improved by 1.3 points. Social roles and activities showed one of the clearest advantages, with a 2.3-point improvement.
Fatigue also improved in the intervention group, with a between arm difference of 1.7 points favoring weight loss intervention. Anxiety, depression, sleep disturbance, and pain interference did not differ significantly between groups at 6 months.
Benefits Generally Maintained At 24 Months
The quality-of-life benefits seen at 6 months were generally maintained at 24 months, and longitudinal mixed modeling produced similar findings. These results suggest that a structured lifestyle-based weight loss intervention can provide measurable functional and symptom benefits for patients with breast cancer, beyond standard health education.
Future BWEL analyses will evaluate which patient populations benefited most, and how weight loss, symptoms, and breast cancer quality of life relate over time.
Reference
Ligibel JA et al. Effect of a weight loss intervention (WLI) on quality of life (QOL) and symptoms in women with breast cancer: Results from the Breast Cancer Weight Loss (BWEL) trial. Abstract 12010. ASCO Annual Meeting, 2026.
Featured Image: Prostock-studio on Adobe Stock.
- Author:
